Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash from Financing Activities: 2014-2025

Historic Cash from Financing Activities for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to $253,000.

  • CytomX Therapeutics' Cash from Financing Activities was N/A to $253,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $101.2 million, marking a year-over-year change of. This contributed to the annual value of $7.5 million for FY2024, which is 75.12% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Cash from Financing Activities of $253,000 as of Q3 2025, which was down 99.73% from $93.5 million recorded in Q2 2025.
  • CytomX Therapeutics' Cash from Financing Activities' 5-year high stood at $108.7 million during Q1 2021, with a 5-year trough of $7,000 in Q1 2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $1.3 million (2023), whereas its average is $16.4 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 4,941.03% in 2021, then crashed by 99.99% in 2022.
  • Quarterly analysis of 5 years shows CytomX Therapeutics' Cash from Financing Activities stood at $683,000 in 2021, then plummeted by 72.18% to $190,000 in 2022, then increased by 28.42% to $244,000 in 2023, then surged by 821.72% to $2.2 million in 2024, then surged by 1,734.67% to $253,000 in 2025.
  • Its last three reported values are $253,000 in Q3 2025, $93.5 million for Q2 2025, and $2.2 million during Q4 2024.